Company
Lifordi
Lifordi Is Pioneering a Targeted Approach to Enhance Delivery to the Immune System.
Also known as Lifordi Immunotherapeutics
- Status
- Operatingas of 2026-09-17Source (opens in a new tab)
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Lifordi is a clinical-stage biotech company developing ADCs that target immune cells to treat autoimmune and inflammatory disorders with precision.
Funding snapshot
- Latest round
- Undisclosed2025-11
Funding rounds
- Round, 2025
- 2025-11
Products
- Other
- LFD-200
- Web
- LFD-200
Loading relationship preview